Some 800 seniors in 14 active ageing centres to benefit from new dementia prevention programme
The dementia prevention community programme will be rolled out to 14 active ageing centres by 2029. ST PHOTO: AZMI ATHNI
Some 800 seniors in 14 active ageing centres to benefit from new dementia prevention programme
SINGAPORE – About 800 seniors with mild or no cognitive impairment and their caregivers are set to benefit from a dementia prevention community programme which will be rolled out to 14 active ageing centres (AACs) by 2029.
The IMPRESS-MIND2S programme is funded to the tune of about $3 million by the National Innovation Challenge on Active and Confident Ageing grant.
It is slated to be piloted at the NTUC Health active ageing centre in Redhill in August 2025 for a start, with 60 seniors benefiting from the programme.
The initiative, launched by healthcare cluster SingHealth, was announced by Senior Minister of State for Health Tan Kiat How on May 30 at the SingHealth Community Forum held at Singapore General Hospital.
Under the programme, community nurses will use established screening tools like tests to detect those who have mild cognitive impairment and will benefit from the programme.
These selected seniors will then receive personalised health coaching to manage dementia risk factors like diet, exercise, stress management and sleep; and have structured physical activity sessions at AACs.
Seniors will also use elderly-friendly tablets called SilverPads to play specially designed games to improve their memory and executive function. Their caregivers will also receive education and support – for example, referrals to respite care and caregiver support groups – to lighten caregiver burden.
All in, seniors are expected to attend about three sessions at their AACs a week.
SingHealth worked with community partners such as Thye Hua Kwan Moral Charities, Montfort Care, NTUC Health and Alkin Singapore to co-create the programme.
Mr Tan pointed out that based on the second Well-being of the Singapore Elderly study, in 2023, one in 11 seniors aged 60 years and above had dementia.
'This goes beyond another health programme: it is a personalised approach to detecting and delaying cognitive decline, working with seniors who have mild or no cognitive impairment, and their caregivers.
' What makes this approach different from others is how it weaves interventions into daily life, with activities designed to naturally fit into seniors' existing routines,' said Mr Tan.
Prof Low Lien Leng, director at SingHealth Centre for Population Health Research and Implementation, said that there is strong evidence that if dementia risk factors are controlled and cognitive function is improved, the risk of developing dementia is lowered.
But such measures have not been implemented in the community, and the pilot will offer insights on how that can be done while keeping seniors interested and engaged.
Join ST's WhatsApp Channel and get the latest news and must-reads.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Straits Times
a day ago
- Straits Times
Polyclinic patients to trial AI tool that reads heart rate and blood pressure with just a phone camera
By analysing a 30-second video of a user's face, the tool is able to detect levels of blood flow in specific facial regions such as the forehead, cheeks and nose. PHOTO: SINGHEALTH POLYCLINICS Polyclinic patients to trial AI tool that reads heart rate and blood pressure with just a phone camera SINGAPORE - An artificial intelligence tool that allows people to measure their heart rate and blood pressure with just a phone camera will be tested by a group of polyclinic patients in the coming months. DeepHealthVision, developed by South Korean digital health company injewelme, will be trialled here in collaboration with SingHealth Polyclinics (SHP). By analysing a 30-second video of a user's face, the tool can detect levels of blood flow in specific facial regions such as the forehead, cheeks and nose, producing accurate readings of both heart rate and blood pressure without the need for external medical devices such as blood pressure monitors and oximeters. 'For example, someone who has high blood pressure or heart rate commonly presents with flushed skin,' said injewelme's chief business development officer Nathan Cheong on June 20, at the 10th Asia Pacific Primary Care Research Conference 2025 held at Academia at the Singapore General Hospital Campus. The accuracy of measurement is not affected by skin colour, he added. Apart from phones, patients can also use the cameras in other devices such as laptops and tablets. Clinical Associate Professor Tan Ngiap Chuan, director of research and Primary Care Research Institute at SHP, said this would make healthcare monitoring more accessible and convenient by eliminating the need for expensive medical devices and frequent clinic visits. A check by The Straits Times found that digital blood pressure monitors can cost anywhere between $50 and $300. 'This system also facilitates continuous remote health monitoring, allowing healthcare professionals to detect health issues before they become serious, enable earlier intervention, and potentially reducing hospitalisations,' said Prof Tan. Mr Cheong said there are also plans to integrate injewelme's AI prediction model DeepHealthNet into DeepHealthVision, which would allow healthcare professionals to access patients' vital signs so that they can make more informed clinical decisions, instead of relying only on limited information collected during visits to the doctor. More than 100,000 people in South Korea have tested out DeepHealthVision, while around 30 healthcare professionals in Singapore were able to try their hand at it during a recent live demonstration . During the demonstration here, the accuracy of DeepHealthVision's heart rate and blood pressure readings was around 96 per cent, when compared with readings taken by Omron blood pressure monitors or Samsung Galaxy smartwatches, said Mr Cheong. Prof Tan said around 60 polyclinic patients will be involved in the pilot test of this tool in the coming months, which would include those with and without hypertension, and others who are interested in knowing more about their own vascular health. He said: 'We want to find out whether local patients are confident in using the technology, whether they accept it, and if they have any concerns. Because if they have concerns, they might not use it on a regular basis.' The pilot test is expected to run for at least a year, during which the data collected will be analysed and subjected to peer review. If the trial is successful, DeepHealthVision may be integrated into healthcare apps such as Health Buddy in the future. The team is also working to enable blood glucose monitoring and skin analysis down the line. In May, SHP also signed memorandums of understanding with two other South Korean companies, YoungAnd and Monit. SHP is collaborating with YoungAnd on Brain Health Playground, an interactive platform designed for patients to play games that support cognitive function. SHP will also trial a tool developed by Monit to assess diaper contamination levels with the use of sensors and an AI-driven pattern learning algorithm. Join ST's WhatsApp Channel and get the latest news and must-reads.
Straits Times
a day ago
- Straits Times
AI tool that measures heart rate and blood pressure via camera to be trialled by polyclinic patients
By analysing a 30-second video of a user's face, the tool is able to detect levels of blood flow in specific facial regions such as the forehead, cheeks, and nose. PHOTO: SINGHEALTH POLYCLINICS AI tool that measures heart rate and blood pressure via camera to be trialled by polyclinic patients SINGAPORE - An artificial intelligence (AI) tool that allows people to measure their heart rate and blood pressure with just a phone camera will be tested by a group of polyclinic patients in the coming months. DeepHealthVision , which SingHealth Polyclinics (SHP) and South Korean digital health company injewelme are collaborating on, was announced during the first day of the 10th Asia Pacific Primary Care Research Conference 2025 on June 20 . The tool, which is able to detect blood flow changes in facial regions such as the forehead and cheeks, can produce vital sign readings without the need for external medical devices such as blood pressure monitors. Apart from phones, patients can also use the cameras in other devices such as laptops and tablets. This would make healthcare monitoring more accessible and convenient by eliminating the need for expensive medical devices and frequent clinic visits, said Clinical Associate Professor Tan Ngiap Chuan, director of research and Primary Care Research Institute at SHP. A check by The Straits Times found that digital blood pressure monitors can cost anywhere between $50 and $300. 'This system also facilitates continuous remote health monitoring, allowing healthcare professionals to detect health issues before they become serious, enable earlier intervention, and potentially reducing hospitalisations,' said Prof Tan. More than 100,000 people in South Korea have tested out DeepHealthVision, and around 30 healthcare professionals in Singapore were able to try their hand at it during a recent live demonstration . The heart rate and blood pressure readings were around 96 per cent accurate during the local test, as compared to readings taken by Omron blood pressure monitors or Samsung Galaxy smartwatches, said injewelme's chief business development officer Nathan Cheong . By analysing a 30-second video of a user's face, the tool is able to detect levels of blood flow in specific facial regions such as the forehead, cheeks, and nose. 'For example, someone who has high blood pressure or heart rate commonly presents with flushed skin,' said Mr Cheong, adding that the accuracy of measurement is not affected by skin colour. The team is also working to enable blood glucose monitoring and skin analysis in the future. Around 60 polyclinic patients will be involved in a pilot test of this tool in the coming months, which would include those with and without hypertension, and others that are interested in knowing more about their own vascular health, said Prof Tan. He said: 'We want to find out whether local patients are confident in using the technology, whether they accept it, and if they have any concerns. Because if they have concerns, they might not use it on a regular basis.' The pilot test is expected to run for a minimum of one year , during which the data collected will be analysed and subjected to peer review. The goal of the pilot is to have at least 96 per cent accuracy of readings, which would give clinicians and patients the confidence to use the tool, said Prof Tan. If the trial is successful, DeepHealthVision may be integrated into healthcare apps such as Health Buddy in the future. Apart from injewelme, SHP also signed memorandums of understanding (MOUs) with two other South Korean companies, YoungAnd and Monit. SHP is collaborating with YoungAnd on Brain Health Playground, an interactive platform designed for patients to play games that support cognitive function. Its collaboration with Monit focuses on a physical tool that uses sensors and an AI -driven pattern learning algorithm to assess diaper contamination levels . Join ST's Telegram channel and get the latest breaking news delivered to you.
CNA
2 days ago
- CNA
Singapore launches national genetic testing programme for inherited cholesterol condition
SINGAPORE: Singapore will on Jun 30 start a national genetic testing programme for an inherited cholesterol condition, the Ministry of Health (MOH) said on Thursday (Jun 19). The programme aims to identify individuals with familial hypercholesterolaemia (FH) early and reduce the risk of premature heart disease for these individuals with timely interventions. An estimated 20,000 people in Singapore have FH, a condition that affects the body's ability to process cholesterol. People with FH face a "significantly higher risk" – up to 20 times more – of experiencing heart attacks at a younger age compared with the general population. It is a hereditary condition. MOH plans to open three Genomic Assessment Centres (GAC) within each of the three healthcare clusters. The first, operated by SingHealth, will be located at the National Heart Centre. It will start accepting referrals from Jun 30. Two other centres, operated by the National Healthcare Group and National University Health System, will be opened subsequently. Individuals referred to these centres will undergo pre-test genetic counselling to understand potential outcomes and benefits before the test, the drawing of blood and the test. They will also get post-test genetic counselling to understand the implications of the results. WHO QUALIFIES? Singaporeans and permanent residents with "abnormally high" cholesterol levels may be referred by their doctors to the GAC for FH genetic testing. Abnormally high levels refer to LDL-C levels of more than or equal to 5.5mmol/L or 212mg/dL. If a person tests positive for FH, their immediate family members – parents, siblings and children – will be at risk and are encouraged to undergo genetic testing. This process is known as cascade screening and enables early detection of FH within families. "In turn, it allows for timelier intervention and treatment, such as advising them to adopt healthier lifestyles and starting them on cholesterol-lowering therapies, if necessary, to reduce their risk of premature heart disease," said MOH. In a Facebook post on Thursday, Health Minister Ong Ye Kung said: "We want to expand preventive care based on genetic testing to more diseases, beyond FH. "It is part of our longer-term effort to develop predictive preventive care under Healthier SG." HOW MUCH WILL IT COST? The costs for FH genetic testing include the drawing of blood, tests, as well as pre-test and post-test counselling. At the GACs, eligible Singaporeans and permanent residents can get means-tested subsidies of up to 70 per cent for these costs. Seniors from the Pioneer Generation and Merdeka Generation are eligible for additional subsidies. After subsidies, patients who are referred to do FH testing can expect to pay between S$117 (US$91) and S$575. Eligible immediate family members of those who have tested positive for FH can expect to pay between S$53 and S$253 after subsidies. MediSave500/700 can be used to further offset the cost of the genetic test after subsidies. Patients who are 60 and above may also use Flexi-MediSave to further defray out-of-pocket costs. Most patients who test positive for FH will require a combination of medication and lifestyle modifications, such as dietary changes and physical activity, to achieve a healthy cholesterol level and prevent premature heart disease, MOH said. "Patients are advised to follow up with a primary care provider at the polyclinics or general practitioner (GP) clinics, or with their family doctor if they are enrolled in Healthier SG for continued management. Subsidies are available for selected chronic medications," it added. INSURANCE A moratorium on genetic testing and insurance was introduced by MOH and the Life Insurance Association Singapore (LIA) in October 2021. Under this agreement, life insurers in Singapore are not allowed to use predictive genetic test results in assessing or deciding the outcome of insurance applications, unless certain criteria are satisfied. Insurers are also not allowed to use genetic test results from biomedical research or direct-to-consumer genetic test results MOH has worked with the LIA to amend the moratorium to disallow life insurers in Singapore from using the results of all genetic tests - both predictive and diagnostic - conducted under the national FH genetic testing programme. "As with standard insurance underwriting practice, they may however request individuals to disclose existing diagnosed conditions (including FH) and family history.
